A Study in Participants With Moderate to Severe Psoriasis

Completed · Phase 2 · Has a placebo group

Conditions studied: Psoriasis

In brief

The primary purpose for this study is to help answer the following research questions * The safety of ixekizumab (LY2439821) and any side effects that might be associated with it. * Whether ixekizumab can help participants with Psoriasis. * How much ixekizumab should be given to participants.

Key facts

Study ID
NCT01107457
Run by
Eli Lilly and Company
People needed
142
Starts
2010-04-01
Expected to finish
2016-07-01
Last updated by the study team
2019-09-24

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.